| Year |
Citation |
Score |
| 2020 |
Phillips RO, Robert J, Abass KM, Thompson W, Sarfo FS, Wilson T, Sarpong G, Gateau T, Chauty A, Omollo R, Ochieng Otieno M, Egondi TW, Ampadu EO, Agossadou D, Marion E, ... ... Grosset J, et al. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet (London, England). PMID 32171422 DOI: 10.1016/S0140-6736(20)30047-7 |
0.376 |
|
| 2019 |
Saini V, Ammerman NC, Chang YS, Tasneen R, Chaisson RE, Jain S, Nuermberger E, Grosset JH. Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 30936097 DOI: 10.1128/Aac.00388-19 |
0.493 |
|
| 2018 |
Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. Antimicrobial Agents and Chemotherapy. PMID 30559131 DOI: 10.1128/AAC.02171-18 |
0.449 |
|
| 2018 |
Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset JH, Nuermberger EL. High-dose rifamycins enable shorter oral treatment in a murine model of disease. Antimicrobial Agents and Chemotherapy. PMID 30455239 DOI: 10.1128/AAC.01478-18 |
0.364 |
|
| 2018 |
Mieras LF, Taal AT, van Brakel WH, Cambau E, Saunderson PR, Smith WCS, Prakoeswa CRS, Astari L, Scollard DM, do Nascimento DC, Grosset J, Kar HK, Izumi S, Gillini L, Virmond MCL, et al. An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+. Bmc Infectious Diseases. 18: 506. PMID 30290790 DOI: 10.1186/S12879-018-3402-4 |
0.435 |
|
| 2018 |
Shapiro AE, Hong T, Govere S, Thulare H, Moosa MY, Dorasamy A, Wallis CL, Celum CL, Grosset J, Drain PK. C-reactive protein as a screening test for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy in South Africa. Aids (London, England). PMID 29847333 DOI: 10.1097/Qad.0000000000001902 |
0.393 |
|
| 2018 |
Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF, Guo H, Chang YS, Li SY, Tapley A, Tasneen R, Tyagi S, Betoudji F, Moodley C, Ngcobo B, ... ... Grosset JH, et al. Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 29735562 DOI: 10.1128/Aac.00636-18 |
0.441 |
|
| 2016 |
Ammerman NC, Swanson RV, Tapley A, Moodley C, Ngcobo B, Adamson J, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. The Journal of Antimicrobial Chemotherapy. PMID 27798204 DOI: 10.1093/Jac/Dkw417 |
0.432 |
|
| 2016 |
Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E. Mutations in pepQ Confer Low-level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 27185800 DOI: 10.1128/Aac.00753-16 |
0.433 |
|
| 2016 |
Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ, Shea TP, Almeida DV, Manson AL, Salazar A, Padayatchi N, O'Donnell MR, Mlisana KP, Wortman J, Birren BW, ... Grosset J, et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nature Genetics. PMID 27064254 DOI: 10.1038/Ng.3548 |
0.418 |
|
| 2016 |
Swanson R, Ammerman N, Ngcobo B, Adamson J, Moodley C, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida D, Grosset J. Clofazimine contributes sustained antimicrobial activity after treatment cessation in the mouse model of tuberculosis chemotherapy. Antimicrobial Agents and Chemotherapy. PMID 26926638 DOI: 10.1128/Aac.00177-16 |
0.524 |
|
| 2015 |
Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, Chapman SB, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, ... ... Grosset J, et al. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. Plos Medicine. 12: e1001880. PMID 26418737 DOI: 10.1371/Journal.Pmed.1001880 |
0.499 |
|
| 2015 |
Kling A, Lukat P, Almeida DV, Bauer A, Fontaine E, Sordello S, Zaburannyi N, Herrmann J, Wenzel SC, König C, Ammerman NC, Barrio MB, Borchers K, Bordon-Pallier F, Brönstrup M, ... ... Grosset JH, et al. Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins. Science (New York, N.Y.). 348: 1106-12. PMID 26045430 DOI: 10.1126/Science.Aaa4690 |
0.42 |
|
| 2015 |
Converse PJ, Tyagi S, Xing Y, Li SY, Kishi Y, Adamson J, Nuermberger EL, Grosset JH. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. Plos Neglected Tropical Diseases. 9: e0003823. PMID 26042792 DOI: 10.1371/Journal.Pntd.0003823 |
0.416 |
|
| 2015 |
Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, Moodley S, Mgaga Z, Tapley A, Bester LA, Singh S, Grosset JH, Almeida DV. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 59: 3042-51. PMID 25753644 DOI: 10.1128/Aac.00260-15 |
0.407 |
|
| 2015 |
Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH. Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations. Antimicrobial Agents and Chemotherapy. 59: 2129-35. PMID 25624335 DOI: 10.1128/Aac.04841-14 |
0.369 |
|
| 2015 |
Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proceedings of the National Academy of Sciences of the United States of America. 112: 869-74. PMID 25561537 DOI: 10.1073/Pnas.1416951112 |
0.519 |
|
| 2015 |
Cohen KA, Abeel T, McGuire AM, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, Chapman S, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, ... ... Grosset J, et al. Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa International Journal of Mycobacteriology. DOI: 10.1016/J.Ijmyco.2014.11.028 |
0.452 |
|
| 2014 |
Almeida DV, Tyagi S, Li S, Wallengren K, Pym AS, Ammerman NC, Bishai WR, Grosset JH. Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice. Mycobacterial Diseases : Tuberculosis & Leprosy. 4: 145. PMID 25525563 DOI: 10.4172/2161-1068.1000145 |
0.409 |
|
| 2013 |
Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection. Plos Neglected Tropical Diseases. 7: e2598. PMID 24367713 DOI: 10.1371/journal.pntd.0002598 |
0.334 |
|
| 2013 |
Grosset JH, Ammerman NC. Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207). Expert Review of Anti-Infective Therapy. 11: 649-51. PMID 23879605 DOI: 10.1586/14787210.2013.811848 |
0.395 |
|
| 2013 |
Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. American Journal of Respiratory and Critical Care Medicine. 188: 608-12. PMID 23822735 DOI: 10.1164/Rccm.201304-0753Oc |
0.482 |
|
| 2013 |
Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. American Journal of Respiratory and Critical Care Medicine. 188: 97-102. PMID 23593945 DOI: 10.1164/rccm.201212-2328OC |
0.352 |
|
| 2013 |
Nuermberger EL, Rosenthal IM, Tasneen R, Peloquin CA, Mdluli KE, Karakousis PC, Grosset JH. Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrobial Agents and Chemotherapy. 57: 1104-5. PMID 23341430 DOI: 10.1128/Aac.02216-12 |
0.782 |
|
| 2013 |
Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH. Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. The Journal of Antimicrobial Chemotherapy. 68: 659-65. PMID 23129730 DOI: 10.1093/Jac/Dks421 |
0.35 |
|
| 2012 |
Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, Welch JT, Baughn AS, Jacobs WR, Grosset JH. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. The Indian Journal of Medical Research. 136: 808-14. PMID 23287128 |
0.463 |
|
| 2012 |
Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proceedings of the National Academy of Sciences of the United States of America. 109: 15001-5. PMID 22927424 DOI: 10.1073/Pnas.1203636109 |
0.545 |
|
| 2012 |
Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 16: 1005-14. PMID 22762423 DOI: 10.5588/Ijtld.12.0277 |
0.455 |
|
| 2012 |
Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrobial Agents and Chemotherapy. 56: 4331-40. PMID 22664964 DOI: 10.1128/Aac.00912-12 |
0.807 |
|
| 2012 |
Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrobial Agents and Chemotherapy. 56: 3726-31. PMID 22547623 DOI: 10.1128/AAC.00500-12 |
0.479 |
|
| 2012 |
Grosset JH, Bishai WR. The added effect of thioridazine in the treatment of drug-resistant tuberculosis: Reply International Journal of Tuberculosis and Lung Disease. 16: 1708-1709. DOI: 10.5588/ijtld.12.0616-2 |
0.34 |
|
| 2012 |
Andréjak C, Tyagi S, Almeida D, Nuermberger E, Grosset J. Clarithromycine versus moxifloxacine dans un modèle murin d’infection pulmonaire à Mycobacterium avium complex Revue Des Maladies Respiratoires. 29. DOI: 10.1016/J.Rmr.2011.10.075 |
0.305 |
|
| 2011 |
Ahmad Z, Fraig MM, Pinn ML, Tyagi S, Nuermberger EL, Grosset JH, Karakousis PC. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. The Journal of Antimicrobial Chemotherapy. 66: 1560-6. PMID 21602551 DOI: 10.1093/jac/dkr188 |
0.485 |
|
| 2011 |
Sánchez F, López Colomés JL, Villarino E, Grosset J. New drugs for tuberculosis treatment. Enfermedades Infecciosas Y Microbiología ClíNica. 29: 47-56. PMID 21420567 DOI: 10.1016/S0213-005X(11)70018-0 |
0.369 |
|
| 2011 |
Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. American Journal of Respiratory and Critical Care Medicine. 183: 1254-61. PMID 21330452 DOI: 10.1164/Rccm.201012-1949Oc |
0.777 |
|
| 2011 |
Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrobial Agents and Chemotherapy. 55: 1527-32. PMID 21282447 DOI: 10.1128/AAC.01524-10 |
0.387 |
|
| 2011 |
Ahmad Z, Minkowski A, Peloquin CA, Williams KN, Mdluli KE, Grosset JH, Nuermberger EL. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrobial Agents and Chemotherapy. 55: 1781-3. PMID 21282421 DOI: 10.1128/AAC.01514-10 |
0.316 |
|
| 2011 |
Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. Plos Neglected Tropical Diseases. 5: e933. PMID 21245920 DOI: 10.1371/Journal.Pntd.0000933 |
0.338 |
|
| 2011 |
Chang KC, Leung CC, Grosset J, Yew WW. Treatment of tuberculosis and optimal dosing schedules. Thorax. 66: 997-1007. PMID 21169286 DOI: 10.1136/thx.2010.148585 |
0.384 |
|
| 2011 |
Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, Nuermberger EL. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrobial Agents and Chemotherapy. 55: 56-61. PMID 21078940 DOI: 10.1128/AAC.01260-10 |
0.405 |
|
| 2011 |
Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 55: 239-45. PMID 20937781 DOI: 10.1128/Aac.00849-10 |
0.362 |
|
| 2010 |
Ahmad Z, Pinn ML, Nuermberger EL, Peloquin CA, Grosset JH, Karakousis PC. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. The Journal of Antimicrobial Chemotherapy. 65: 2172-5. PMID 20693172 DOI: 10.1093/jac/dkq277 |
0.397 |
|
| 2010 |
Alffenaar JW, Nienhuis WA, de Velde F, Zuur AT, Wessels AM, Almeida D, Grosset J, Adjei O, Uges DR, van der Werf TS. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrobial Agents and Chemotherapy. 54: 3878-83. PMID 20585115 DOI: 10.1128/Aac.00099-10 |
0.428 |
|
| 2010 |
Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, Klinkenberg LG, Gupta R, Lun S, Karakousis PC, Lamichhane G, ... ... Grosset JH, et al. The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models. Plos One. 5: e10289. PMID 20422019 DOI: 10.1371/Journal.Pone.0010289 |
0.321 |
|
| 2010 |
Olaleye O, Raghunand TR, Bhat S, He J, Tyagi S, Lamichhane G, Gu P, Zhou J, Zhang Y, Grosset J, Bishai WR, Liu JO. Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets. Chemistry & Biology. 17: 86-97. PMID 20142044 DOI: 10.1016/J.Chembiol.2009.12.014 |
0.442 |
|
| 2010 |
Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH, Karakousis PC. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. The Journal of Antimicrobial Chemotherapy. 65: 729-34. PMID 20123722 DOI: 10.1093/jac/dkq007 |
0.444 |
|
| 2009 |
Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. American Journal of Respiratory and Critical Care Medicine. 180: 1151-7. PMID 19729664 DOI: 10.1164/Rccm.200905-0795Oc |
0.816 |
|
| 2009 |
Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, Nuermberger EL, Grosset JH, Karakousis PC. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. The Journal of Infectious Diseases. 200: 1136-43. PMID 19686043 DOI: 10.1086/605605 |
0.462 |
|
| 2009 |
Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 53: 4178-84. PMID 19620331 DOI: 10.1128/Aac.00830-09 |
0.787 |
|
| 2009 |
Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. American Journal of Respiratory and Critical Care Medicine. 180: 371-6. PMID 19520903 DOI: 10.1164/rccm.200904-0611OC |
0.364 |
|
| 2009 |
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine. 180: 273-80. PMID 19406981 DOI: 10.1164/Rccm.200901-0078Oc |
0.441 |
|
| 2009 |
Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A, Dianiskova P, ... ... Grosset J, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science (New York, N.Y.). 324: 801-4. PMID 19299584 DOI: 10.1126/Science.1171583 |
0.493 |
|
| 2009 |
Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrobial Agents and Chemotherapy. 53: 1314-9. PMID 19075058 DOI: 10.1128/AAC.01182-08 |
0.493 |
|
| 2009 |
Be NA, Lamichhane G, Grosset J. Murine model to study the invasion and survival of Mycobacterium tuberculosis in the central nervous system. (Journal of Infectious Diseases (2008) 198, (1520-1528)) Journal of Infectious Diseases. 199: 290. DOI: 10.1086/596032 |
0.402 |
|
| 2008 |
Be NA, Lamichhane G, Grosset J, Tyagi S, Cheng QJ, Kim KS, Bishai WR, Jain SK. Murine model to study the invasion and survival of Mycobacterium tuberculosis in the central nervous system. The Journal of Infectious Diseases. 198: 1520-8. PMID 18956986 DOI: 10.1086/592447 |
0.475 |
|
| 2008 |
Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? American Journal of Respiratory and Critical Care Medicine. 178: 989-93. PMID 18723432 DOI: 10.1164/Rccm.200807-1029Oc |
0.784 |
|
| 2008 |
Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 52: 3664-8. PMID 18694943 DOI: 10.1128/Aac.00686-08 |
0.581 |
|
| 2008 |
Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 52: 1522-4. PMID 18285479 DOI: 10.1128/Aac.00074-08 |
0.803 |
|
| 2007 |
Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. Plos Medicine. 4: e344. PMID 18092886 DOI: 10.1371/Journal.Pmed.0040344 |
0.805 |
|
| 2007 |
Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 51: 4261-6. PMID 17938193 DOI: 10.1128/Aac.01123-07 |
0.509 |
|
| 2007 |
Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Aubry J, Nuermberger E, Grosset J. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrobial Agents and Chemotherapy. 51: 4029-35. PMID 17526760 DOI: 10.1128/Aac.00175-07 |
0.39 |
|
| 2007 |
Jain SK, Hernandez-Abanto SM, Cheng QJ, Singh P, Ly LH, Klinkenberg LG, Morrison NE, Converse PJ, Nuermberger E, Grosset J, McMurray DN, Karakousis PC, Lamichhane G, Bishai WR. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. The Journal of Infectious Diseases. 195: 1634-42. PMID 17471433 DOI: 10.1086/517526 |
0.448 |
|
| 2006 |
Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, Grosset JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 50: 2621-5. PMID 16870750 DOI: 10.1128/Aac.00451-06 |
0.8 |
|
| 2006 |
Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. American Journal of Respiratory and Critical Care Medicine. 174: 94-101. PMID 16574936 DOI: 10.1164/Rccm.200602-280Oc |
0.801 |
|
| 2005 |
Maugein J, Dailloux M, Carbonnelle B, Vincent V, Grosset J, Abalain ML, Bauriaud R, Bemer P, Bourgoin A, Brasme L, Cambau E, Carricajo A, Carriere C, Cattier B, Coignard S, et al. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease European Respiratory Journal. 26: 1092-1096. PMID 16319341 DOI: 10.1183/09031936.05.00148604 |
0.328 |
|
| 2005 |
Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. American Journal of Respiratory and Critical Care Medicine. 172: 1452-6. PMID 16151038 DOI: 10.1164/Rccm.200507-1047Oc |
0.795 |
|
| 2005 |
Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. American Journal of Respiratory and Critical Care Medicine. 172: 1457-62. PMID 16141439 DOI: 10.1164/Rccm.200507-1072Oc |
0.799 |
|
| 2005 |
Ginsburg AS, Sun R, Calamita H, Scott CP, Bishai WR, Grosset JH. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model Antimicrobial Agents and Chemotherapy. 49: 3977-3979. PMID 16127087 DOI: 10.1128/Aac.49.9.3977-3979.2005 |
0.449 |
|
| 2005 |
Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrobial Agents and Chemotherapy. 49: 3182-6. PMID 16048922 DOI: 10.1128/Aac.49.8.3182-3186.2005 |
0.367 |
|
| 2005 |
Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 49: 2289-93. PMID 15917523 DOI: 10.1128/Aac.49.6.2289-2293.2005 |
0.81 |
|
| 2005 |
Casal M, Vaquero M, Rinder H, Tortoli E, Grosset J, Rüsch-Gerdes S, Gutiérrez J, Jarlier V. A Case-Control Study for Multidrug-Resistant Tuberculosis: Risk Factors in Four European Countries Microbial Drug Resistance. 11: 62-67. PMID 15770097 DOI: 10.1089/Mdr.2005.11.62 |
0.429 |
|
| 2005 |
Ginsburg AS, Lee J, Woolwine SC, Grosset JH, Hamzeh FM, Bishai WR. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrobial Agents and Chemotherapy. 49: 853-6. PMID 15673788 DOI: 10.1128/Aac.49.2.853-856.2005 |
0.445 |
|
| 2004 |
Nuermberger E, Bishai WR, Grosset JH. Latent tuberculosis infection. Seminars in Respiratory and Critical Care Medicine. 25: 317-36. PMID 16088473 DOI: 10.1055/S-2004-829504 |
0.41 |
|
| 2004 |
Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J, Bishai WR. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. The Journal of Experimental Medicine. 200: 647-57. PMID 15353557 DOI: 10.1084/Jem.20040646 |
0.503 |
|
| 2004 |
Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. American Journal of Respiratory and Critical Care Medicine. 170: 1131-4. PMID 15306535 DOI: 10.1164/Rccm.200407-885Oc |
0.799 |
|
| 2004 |
Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections European Journal of Clinical Microbiology and Infectious Diseases. 23: 243-255. PMID 15024625 DOI: 10.1007/S10096-004-1109-5 |
0.455 |
|
| 2004 |
Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infection and Immunity. 72: 1065-71. PMID 14742554 DOI: 10.1128/Iai.72.2.1065-1071.2004 |
0.353 |
|
| 2004 |
Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. American Journal of Respiratory and Critical Care Medicine. 169: 421-6. PMID 14578218 DOI: 10.1164/Rccm.200310-1380Oc |
0.5 |
|
| 2003 |
Emmanuelli X, Grosset J. Tuberculosis and poverty Revue Des Maladies Respiratoires. 20: 169-171. PMID 12844011 |
0.38 |
|
| 2003 |
Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. The Lancet. Infectious Diseases. 3: 432-42. PMID 12837348 DOI: 10.1016/S1473-3099(03)00671-6 |
0.383 |
|
| 2003 |
Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrobial Agents and Chemotherapy. 47: 833-6. PMID 12604509 DOI: 10.1128/Aac.47.3.833-836.2003 |
0.475 |
|
| 2003 |
Robert J, Trystram D, Truffot C, Grosset J. La multirésistance (MDR) de Mycobacterium tuberculosis aux antibiotiques en France depuis 1992 MéDecine Et Maladies Infectieuses. 33: 183-187. DOI: 10.1016/S0399-077X(03)00064-7 |
0.313 |
|
| 2003 |
Robert J, Trystram D, Truffot C, Grosset J. Multidrug resistance (MDR) of Mycobacterium tuberculosis in France since 1992 Medecine Et Maladies Infectieuses. 33. |
0.407 |
|
| 2002 |
Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrobial Agents and Chemotherapy. 46: 3193-6. PMID 12234844 DOI: 10.1128/Aac.46.10.3193-3196.2002 |
0.509 |
|
| 2002 |
Grosset J, Zunic L, Morcrette C. [World epidemiology of tuberculosis and resistance against anti-tuberculosis drugs]. Annales De MéDecine Interne. 153: 107-12. PMID 12037492 |
0.385 |
|
| 2002 |
Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrobial Agents and Chemotherapy. 46: 1875-9. PMID 12019103 DOI: 10.1128/Aac.46.6.1875-1879.2002 |
0.53 |
|
| 2002 |
Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrobial Agents and Chemotherapy. 45: 3482-6. PMID 11709328 DOI: 10.1128/AAC.45.12.3482-3486.2001 |
0.438 |
|
| 2002 |
Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrobial Agents and Chemotherapy. 45: 3229-30. PMID 11600387 DOI: 10.1128/Aac.45.11.3229-3230.2001 |
0.477 |
|
| 2002 |
Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrobial Agents and Chemotherapy. 45: 3109-12. PMID 11600364 DOI: 10.1128/Aac.45.11.3109-3112.2001 |
0.496 |
|
| 2001 |
Grosset JH. Newer drugs in leprosy International Journal of Leprosy and Other Mycobacterial Diseases. 69. PMID 11757174 |
0.345 |
|
| 2001 |
Cambau E, Truffot-Pernot C, Boulahbal F, Wichlacz C, Grosset J, Jarlier V. Mycobacterial growth indicator tube versus the proportion method on Löwenstein-Jensen medium for antibiotic susceptibility testing of Mycobacterium tuberculosis. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 19: 938-42. PMID 11205631 DOI: 10.1007/S100960000402 |
0.368 |
|
| 2001 |
Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR. Iron and Mycobacterium tuberculosis infection. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 20: 123-6. PMID 11166659 DOI: 10.1016/S1386-6532(00)00136-0 |
0.374 |
|
| 2000 |
Ji B, Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy Leprosy Review. 71. PMID 11201894 |
0.384 |
|
| 2000 |
Consigny S, Bentoucha A, Bonnafous P, Grosset J, Ji B. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice Antimicrobial Agents and Chemotherapy. 44: 2919-2921. PMID 10991891 DOI: 10.1128/Aac.44.10.2919-2921.2000 |
0.45 |
|
| 2000 |
Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrobial Agents and Chemotherapy. 44: 2367-72. PMID 10952581 DOI: 10.1128/Aac.44.9.2367-2372.2000 |
0.482 |
|
| 2000 |
Daniel N, Lounis N, Ji B, O'Brien RJ, Vernon A, Geiter LJ, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. American Journal of Respiratory and Critical Care Medicine. 161: 1572-7. PMID 10806157 DOI: 10.1164/Ajrccm.161.5.9904090 |
0.492 |
|
| 2000 |
Uffredi ML, Grosset J. Recent data on tuberculosis Medecine Therapeutique. 6: 429-433. |
0.327 |
|
| 1999 |
Lounis N, Ji B, Truffot-Pernot C, Ridley RG, Alber G, Grosset JH. Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 5: 331-338. PMID 11856278 |
0.373 |
|
| 1999 |
Ji B, Grosset JH. Drugs and regimens for preventive therapy against tuberculosis, disseminated Mycobacterium avium complex infection and leprosy International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association. 67. PMID 10700937 |
0.38 |
|
| 1999 |
Grosset J. Which strategies for eradication of tuberculosis? Bulletin De L'Academie Nationale De Medecine. 183: 25-37; discussion 37. PMID 10622120 |
0.39 |
|
| 1999 |
Rinder H, Feldmann K, Tortoli E, Grosset J, Casal M, Richter E, Rifai M, Jarlier V, Vaquero M, Rüsch-Gerdes S, Cambau E, Gutierrez J, Löscher T. Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples Molecular Diagnosis. 4: 145-152. PMID 10462629 DOI: 10.1016/S1084-8592(99)80038-1 |
0.385 |
|
| 1999 |
Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: A nationwide case-control study American Journal of Respiratory and Critical Care Medicine. 160: 587-593. PMID 10430733 DOI: 10.1164/Ajrccm.160.2.9901012 |
0.45 |
|
| 1999 |
Lounis N, Maslo C, Boelaert JR, Bonnafous P, Trnffot-Pernot C, Baohong J, Grosset J. Impact of iron loading and iron chelation on murine tuberculosis Clinical Microbiology and Infection. 5: 687-692. DOI: 10.1111/J.1469-0691.1999.Tb00514.X |
0.373 |
|
| 1999 |
Lounis N, Truffot-Pernot C, Ji B, Grosset J. Pharmacokinetics and animal studies of rifapentine in tuberculosis Drugs of Today. 35: 17-27. |
0.547 |
|
| 1998 |
Jouveshomme S, Cambau E, Trystram D, Szpytma M, Sougakoff W, Derenne JP, Grosset J. Clinical utility of an amplification test based on ligase chain reaction in pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine. 158: 1096-101. PMID 9769266 DOI: 10.1164/Ajrccm.158.4.9801112 |
0.452 |
|
| 1998 |
Schwoebel V, Decludt B, de Benoist AC, Haeghebaert S, Torrea G, Vincent V, Grosset J. Multidrug resistant tuberculosis in France 1992-4: two case-control studies. Bmj (Clinical Research Ed.). 317: 630-1. PMID 9727990 DOI: 10.1136/Bmj.317.7159.630 |
0.419 |
|
| 1998 |
Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 42: 2066-9. PMID 9687408 DOI: 10.1128/Aac.42.8.2066 |
0.578 |
|
| 1998 |
Grosset J, Lounis N, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Ji B. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. American Journal of Respiratory and Critical Care Medicine. 157: 1436-40. PMID 9603120 DOI: 10.1164/Ajrccm.157.5.9709072 |
0.507 |
|
| 1998 |
Ji B, Sow S, Perani E, Lienhardt C, Diderot V, Grosset J. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrobial Agents and Chemotherapy. 42: 1115-20. PMID 9593137 DOI: 10.1128/Aac.42.5.1115 |
0.44 |
|
| 1998 |
Carbonne A, Lemaitre N, Bochet M, Truffot-Pernot C, Katlama C, Grosset J, Bricaire F, Jarlier V. Mycobacterium avium Complex Conmmnon-Source or Cross-Infection in AIDS Patients Attending the Same Day-Care Facility Infection Control and Hospital Epidemiology. 19: 784-786. DOI: 10.2307/30141426 |
0.342 |
|
| 1997 |
May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, Saint-Marc T, Dautzenberg B, Grosset J. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 25: 621-9. PMID 9314450 DOI: 10.1086/513753 |
0.437 |
|
| 1997 |
Ji B, Jamet P, Sow S, Perani EG, Traore I, Grosset JH. High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrobial Agents and Chemotherapy. 41: 1953-6. PMID 9303392 DOI: 10.1128/aac.41.9.1953 |
0.311 |
|
| 1997 |
Mane I, Cartel JL, Grosset JH. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results International Journal of Leprosy. 65: 224-229. PMID 9251595 |
0.335 |
|
| 1997 |
Lounis N, Ji B, Truffot-Pernot C, Grosset J. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice Antimicrobial Agents and Chemotherapy. 41: 1168-1169. PMID 9145892 DOI: 10.1128/Aac.41.5.1168 |
0.405 |
|
| 1997 |
Lounis N, Ji B, Truffot-Pernot C, Grosset J. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrobial Agents and Chemotherapy. 41: 607-610. PMID 9056001 DOI: 10.1128/Aac.41.3.607 |
0.585 |
|
| 1997 |
Dautzenberg B, Truffot-Pernot C, Hazebroucq J, Legris S, Guerin C, Begelman C, Guermonprez G, Fievet MH, Chastang C, Grosset J. A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections Infection. 25: 16-21. PMID 9039532 DOI: 10.1007/Bf02113501 |
0.423 |
|
| 1997 |
Ji B, Jamet P, Perani EG, Sow S, Lienhardt C, Petinon C, Grosset JH. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrobial Agents and Chemotherapy. 40: 2137-41. PMID 8878595 DOI: 10.1128/AAC.40.9.2137 |
0.357 |
|
| 1996 |
Ji B, Lounis N, Truffot-Pernot C, Grosset J. How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? Antimicrobial Agents and Chemotherapy. 40: 437-442. PMID 8834894 DOI: 10.1128/Aac.40.2.437 |
0.494 |
|
| 1996 |
Ji B, Perani EG, Petinom C, Grosset JH. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrobial Agents and Chemotherapy. 40: 393-9. PMID 8834886 DOI: 10.1128/aac.40.2.393 |
0.476 |
|
| 1996 |
Doucet-Populaire F, Lalande V, Carpentier E, Bourgoin A, Dailloux M, Bollet C, Vachée A, Moinard D, Texier-Maugein J, Carbonnelle B, Grosset J. A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group. Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 77: 358-62. PMID 8796253 DOI: 10.1016/S0962-8479(96)90102-1 |
0.352 |
|
| 1996 |
Grosset J. Current problems with tuberculosis treatment Research in Microbiology. 147: 10-16. PMID 8761716 DOI: 10.1016/0923-2508(96)80197-5 |
0.316 |
|
| 1996 |
Truffot-Pernot C, Lounis N, Grosset JH, Ji B. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 39: 2827-8. PMID 8593032 DOI: 10.1128/AAC.39.12.2827 |
0.431 |
|
| 1996 |
Doucet-Populaire F, Truffot-Pernot C, Grosset J, Jarlier V. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. The Journal of Antimicrobial Chemotherapy. 36: 129-36. PMID 8537260 DOI: 10.1093/Jac/36.1.129 |
0.37 |
|
| 1996 |
Baril L, Caumes E, Truffot-Pernot C, Bricaire F, Grosset J, Gentilini M. Tuberculosis caused by Mycobacterium africanum associated with involvement of the upper and lower respiratory tract, skin, and mucosa. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 21: 653-5. PMID 8527560 DOI: 10.1093/Clinids/21.3.653 |
0.444 |
|
| 1996 |
Grosset J. Experimental approach of chemotherapy for tuberculosis Medecine Et Maladies Infectieuses. 26: 922-925. DOI: 10.1016/S0399-077X(96)80198-3 |
0.5 |
|
| 1995 |
Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: Why and how? Tubercle and Lung Disease. 76: 487-492. PMID 8593368 DOI: 10.1016/0962-8479(95)90523-5 |
0.311 |
|
| 1995 |
Cohen Y, Perronne C, Lazard T, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ. Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. Antimicrobial Agents and Chemotherapy. 39: 735-8. PMID 7793882 DOI: 10.1128/Aac.39.3.735 |
0.441 |
|
| 1995 |
Lounis N, Ji B, Truffot-Pernot C, Grosset J. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model Antimicrobial Agents and Chemotherapy. 39: 608-612. PMID 7793860 |
0.408 |
|
| 1995 |
Struillou L, Cohen Y, Lounis N, Bertrand G, Grosset J, Vildé JL, Pocidalo JJ, Perronne C. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrobial Agents and Chemotherapy. 39: 878-81. PMID 7785988 DOI: 10.1128/AAC.39.4.878 |
0.349 |
|
| 1995 |
Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis Antimicrobial Agents and Chemotherapy. 39: 1341-1344. PMID 7574527 |
0.456 |
|
| 1995 |
Decludt B, Schwoebel V, Haeghebaert S, Grosset J. 114-PC11/12 Pilot study for surveillance of drug resistant Mycobacterium tuberculosis in France Tubercle and Lung Disease. 76: 96-97. DOI: 10.1016/0962-8479(95)90365-8 |
0.46 |
|
| 1995 |
Schwoebel V, Decludt B, Haeghebaert S, Torrea G, Vincent V, Grosset J. 291-PA11 Multi-drug resistant tuberculosis in France (1992–1994) Tubercle and Lung Disease. 76: 92-93. DOI: 10.1016/0962-8479(95)90353-4 |
0.444 |
|
| 1994 |
Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, Roscigno G, Grosset J. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. The American Review of Respiratory Disease. 148: 1541-6. PMID 8256897 DOI: 10.1164/Ajrccm/148.6_Pt_1.1541 |
0.538 |
|
| 1994 |
Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V. Selection of a gyrA Mutant of Mycobacterium tuberculosis Resistant to Fluoroquinolones during Treatment with Ofloxacin The Journal of Infectious Diseases. 170: 479-483. PMID 8035042 DOI: 10.1093/Infdis/170.2.479 |
0.423 |
|
| 1994 |
Ji B, Perani EG, Petinom C, N'Deli L, Grosset JH. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrobial Agents and Chemotherapy. 38: 662-7. PMID 8031029 DOI: 10.1128/AAC.38.4.662 |
0.324 |
|
| 1994 |
Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. American Journal of Respiratory and Critical Care Medicine. 150: 1355-62. PMID 7952564 DOI: 10.1164/ajrccm.150.5.7952564 |
0.419 |
|
| 1994 |
Lazard T, Perronne C, Truffot-Pernot C, Grosset J, Vildé JL, Pocidalo JJ. Chloroquine does not enhance the activity of clarithromycin against multiplication of Mycobacterium avium within human macrophages. Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 75: 283-5. PMID 7949074 DOI: 10.1016/0962-8479(94)90133-3 |
0.451 |
|
| 1994 |
Ji B, Lounis N, Truffot-Pernot C, Grosset J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model Antimicrobial Agents and Chemotherapy. 38: 2521-2529. PMID 7872741 |
0.369 |
|
| 1994 |
Truffot-Pernot C, Grosset J. Bacteriology for diagnosis of tuberculosis Medecine Et Maladies Infectieuses. 24: 871-873. DOI: 10.1016/S0399-077X(05)80575-X |
0.345 |
|
| 1994 |
Schwoebel V, Papillon F, Haeghebaert S, Truffot-Pernot C, Grosset J. Surveillance of multi-drug resistant tuberculosis in france in 1992 Tubercle and Lung Disease. 75: 19. DOI: 10.1016/0962-8479(94)90750-1 |
0.445 |
|
| 1994 |
Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V. Acquired resistance of mycobacterium tuberculosis to fluoroquinolones Tubercle and Lung Disease. 75: 12. DOI: 10.1016/0962-8479(94)90724-2 |
0.467 |
|
| 1994 |
Schwoebel V, Grosset J, Hubert B. Tuberculous menigistis in France in 1990 Tubercle and Lung Disease. 75: 461. DOI: 10.1016/0962-8479(94)90123-6 |
0.375 |
|
| 1993 |
Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrobial Agents and Chemotherapy. 37: 407-13. PMID 8384811 DOI: 10.1128/AAC.37.3.407 |
0.497 |
|
| 1993 |
Ji B, Jamet P, Perani EG, Bobin P, Grosset JH. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. The Journal of Infectious Diseases. 168: 188-90. PMID 8257487 DOI: 10.1093/infdis/168.1.188 |
0.34 |
|
| 1993 |
Lazard T, Perronne C, Grosset J, Vilde JL, Pocidalo JJ. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. Antimicrobial Agents and Chemotherapy. 37: 1690-2. PMID 8215285 DOI: 10.1128/Aac.37.8.1690 |
0.443 |
|
| 1993 |
Verduin PRN, Grosset JH. Isoniazid and hepatotoxicity [1] International Journal of Leprosy. 61: 628-629. PMID 8179715 |
0.317 |
|
| 1993 |
Lazard T, Perronne C, Cohen Y, Grosset J, Vilde JL, Pocidalo JJ. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Antimicrobial Agents and Chemotherapy. 37: 692-5. PMID 7684213 DOI: 10.1128/AAC.37.4.692 |
0.314 |
|
| 1993 |
Perronne C, Cohen Y, Truffot-Pernot C, Grosset J, Vildé JL, Pocidalo JJ. Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice. Antimicrobial Agents and Chemotherapy. 36: 2408-12. PMID 1336944 DOI: 10.1128/Aac.36.11.2408 |
0.471 |
|
| 1993 |
Lazard T, Perronne C, Grosset J, Vilde J, Pocidalo J. Clarithromycin, Minocycline, and Rifabutin Treatments before and after Infection of C57BL/6 Mice with Mycobacterium avium Antimicrobial Agents and Chemotherapy. 37: 2515-2515. DOI: 10.1128/aac.37.11.2515 |
0.328 |
|
| 1992 |
Dautzenberg B, Truffot C, Mignon A, Rozenbaum W, Katlama C, Perronne C, Parrot R, Grosset J. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes. Tubercle. 72: 168-75. PMID 1663282 DOI: 10.1016/0041-3879(91)90002-A |
0.449 |
|
| 1992 |
Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice Antimicrobial Agents and Chemotherapy. 36: 548-551. PMID 1622164 DOI: 10.1128/Aac.36.3.548 |
0.525 |
|
| 1992 |
Ji B, Lounis N, Truffot-Pernot C, Grosset J. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy Antimicrobial Agents and Chemotherapy. 36: 2839-2840. PMID 1482155 |
0.308 |
|
| 1991 |
Truffot-Pernot C, Ji B, Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments Tubercle. 72: 57-64. PMID 1909062 DOI: 10.1016/0041-3879(91)90025-N |
0.425 |
|
| 1991 |
Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, Chevret S, Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. The American Review of Respiratory Disease. 144: 564-9. PMID 1832527 DOI: 10.1164/Ajrccm/144.3_Pt_1.564 |
0.405 |
|
| 1991 |
Ji B, Perani EG, Grosset JH. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrobial Agents and Chemotherapy. 35: 579-81. PMID 1828136 DOI: 10.1128/AAC.35.3.579 |
0.308 |
|
| 1991 |
Ji B, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis Tubercle. 72: 181-186. PMID 1663283 DOI: 10.1016/0041-3879(91)90004-C |
0.39 |
|
| 1991 |
Grosset J, Truffot-Pernot C, Boisvert H, Lalande V. What are atypical mycobacteria ? Medecine Et Maladies Infectieuses. 21: 7-15. DOI: 10.1016/S0399-077X(05)80113-1 |
0.315 |
|
| 1990 |
Grosset J. Bacteriologic basis for the treatment of tuberculosis Revue Du Praticien. 40: 715-718. PMID 2320895 |
0.428 |
|
| 1990 |
Grosset J. Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis Bulletin of the International Union Against Tuberculosis and Lung Disease. 65: 86-91. PMID 2257371 |
0.36 |
|
| 1990 |
Grosset J. New experimental regimens for preventive therapy of tuberculosis Bulletin of the International Union Against Tuberculosis and Lung Disease. 66: 15-16. PMID 1983742 |
0.345 |
|
| 1989 |
Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. The American Review of Respiratory Disease. 140: 1189-93. PMID 2817579 DOI: 10.1164/ajrccm/140.5.1189 |
0.435 |
|
| 1989 |
Jarlier V, Nicolas MH, Philippon A, Giroir AM, Grosset J. In-vitro activity of FCE 22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation cephalosporins. The Journal of Antimicrobial Chemotherapy. 24: 165-72. PMID 2676939 DOI: 10.1093/Jac/24.2.165 |
0.312 |
|
| 1989 |
Grosset JH. Present Status of Chemotherapy for Tuberculosis Reviews of Infectious Diseases. 11: S347-S352. PMID 2652251 DOI: 10.1093/clinids/11.Supplement_2.S347 |
0.448 |
|
| 1988 |
Lepetit C, Thebaud-Mony A, Grosset J. Tuberculosis in the 'Seine-Saint-Denis'. 1. Cases treated in 1984 Revue Des Maladies Respiratoires. 5: 129-136. PMID 3393707 |
0.341 |
|
| 1988 |
Grosset JH, Truffot-Pernot C, Lecoeur H. Pulmonary tuberculosis - New and future therapeutic aspects Praxis Und Klinik Der Pneumologie. 42: 206-210. PMID 3174565 |
0.478 |
|
| 1988 |
Mitchison DA, Ellard GA, Grosset J. New antibacterial drugs for the treatment of mycobacterial disease in man British Medical Bulletin. 44: 757-774. PMID 3076819 |
0.376 |
|
| 1988 |
Truffot-Pernot C, Giroir AM, Grosset J. A study of the minimal inhibitory concentration of rifabutin (ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulaire Revue Des Maladies Respiratoires. 5: 401-406. PMID 2845531 |
0.364 |
|
| 1987 |
Grosset J. Short-course chemotherapy of tuberculosis Medecine Et Maladies Infectieuses. 17: 795-798. |
0.433 |
|
| 1985 |
Grosset J, Truffot-Pernot C, Poggi S. The prevention of rifampicin resistance with pyrazinamide Revue Des Maladies Respiratoires. 2: 205-208. PMID 3937188 |
0.391 |
|
| 1985 |
Grosset J, Lecoeur H, Truffot-Pernot C, Jarlier V. Physiopathology of tuberculous meningitis Medecine Et Maladies Infectieuses. 15: 593-596. DOI: 10.1016/S0399-077X(85)80019-6 |
0.337 |
|
| 1984 |
Grosset J. Advances in leprosy chemotherapy Medecine Tropicale. 44: 17-22. PMID 6377002 |
0.305 |
|
| 1984 |
Dautzenberg B, Grosset J, Fechner J, Lucciani J, Debre P, Herson S, Truffot C, Sors C. The management of thirty immunocompromised patients with tuberculosis. The American Review of Respiratory Disease. 129: 494-6. PMID 6367575 DOI: 10.1164/arrd.1984.129.3.494 |
0.312 |
|
| 1983 |
Grosset J, Guelpa-Lauras CC, Lecoeur H. Microbial persistence in mycobacterial infections Quaderni Di Cooperazione Sanitaria. 41-49. |
0.431 |
|
| 1982 |
Grosset J, Truffot C, Boval C, Urbanczik R. The role of low dosage prothionamide with and without 4,4'-diaminio dipheimyl sulphone for use with isoniazld in the treatment of experimental mouse tuberculosis Tubercle. 63: 37-43. PMID 7080212 DOI: 10.1016/S0041-3879(82)80007-X |
0.51 |
|
| 1982 |
Sors C, Dautzenberg B, Grosset J. Duration of anti-tuberculous treatment in 1981 Nouvelle Presse Medicale. 11: 831. PMID 7070974 |
0.337 |
|
| 1982 |
Grosset J, Truffot-Pernot C. Laboratories: their role in the diagnosis and treatment of tuberculosis Bulletin of the International Union Against Tuberculosis. 57: 234-241. PMID 6820294 |
0.36 |
|
| 1982 |
Grosset J, Truffot C, Fermanian J, Lecoeur H. Sterilizing activity of the main drugs on the mouse experimental tuberculosis Pathologie Biologie. 30: 444-448. PMID 6810288 |
0.484 |
|
| 1982 |
Grosset J, Truffot-Pernot C. Biology of the tuberculosis bacillus Revue Medicale De La Suisse Romande. 102: 257-263. PMID 6808636 |
0.329 |
|
| 1982 |
Grosset J. The recrudescence of pulmonary tuberculosis Gazette Medicale De France. 89: 4049-4050. |
0.307 |
|
| 1982 |
Sors C, Grosset J. Therapeutic programmes in pulmonary tuberculosis Gazette Medicale De France. 89: 4075-4080. |
0.416 |
|
| 1982 |
Truffot-Pernot C, Grosset J. Bacteriology of tuberculosis Medecine Et Hygiene. 40: 1493-1501. |
0.391 |
|
| 1982 |
Grosset J, Truffot Pernot C. The role of the laboratory in the diagnosis and treatment of tuberculosis Bulletin of the International Union Against Tuberculosis. 57: 226-234. |
0.387 |
|
| 1981 |
Lecoeur H, Lagrange PH, Truffot C, Grosset J. Microbial persistence and tuberculin hypersensitivity after chemotherapy of the mouse experimental tuberculosis Annales D'Immunologie. 132: 237-248. |
0.37 |
|
| 1980 |
Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis Clinics in Chest Medicine. 1: 231-241. PMID 6794976 |
0.378 |
|
| 1980 |
Grosset J. The efficacy of short-course chemotherapy for tuberculosis Bulletin of the Pan American Health Organization. 14: 139-149. PMID 6774794 |
0.392 |
|
| 1980 |
Grosset J, Truffot C, Boval C, Fermanian J. Sterilizing activity of isoniazid and pyrazinamide in combination with rifampicin in the experimental tuberculosis of the mouse Revue Francaise Des Maladies Respiratoires. 8: 31-32. |
0.46 |
|
| 1979 |
Grosset J. Bacteriologic principles of treatment of tuberculosis Revue Du Praticien. 29: 2645-2650. PMID 113863 |
0.311 |
|
| 1979 |
Grosset J. Activity and effectiveness of antituberculosis drugs Lyon Medical. 241: 567-573. |
0.315 |
|
| 1978 |
Pretet S, Grosset J, Perdrizet S. Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results) Bulletin of the International Union Against Tuberculosis. 53: 260-261. PMID 387140 |
0.323 |
|
| 1978 |
Grosset J. Short course chemotherapy in experimental tuberculosis Selected Papers of the Royal Netherlands Tuberculosis Association. 5-31. |
0.311 |
|
| 1978 |
Grosset J, Grumbach F, Rist N. The role of rifampicin in the final stage of treatment of experimental tuberculosis in the mouse Revue Francaise Des Maladies Respiratoires. 6: 515-520. |
0.446 |
|
| 1975 |
Grumbach F, Grosset J. Pyrazinamide in short course chemotherapy of murine tuberculosis Revue Francaise Des Maladies Respiratoires. 3: 5-18. |
0.39 |
|
| 1973 |
Sors C, Grosset J. Towards a rational utilization of the means for the campaign against tuberculosis Gestions Hospitalieres. 615-621. |
0.374 |
|
| 1971 |
Grosset J, Decroix G, Sors C. Tuberculosis due to Mycobacterium africanum in African negroes in the Paris area Revue De Tuberculose Et De Pneumologie. 35: 430-436. PMID 5002286 |
0.347 |
|
| 1970 |
de Beco O, Boulahbal F, Grosset J. Incidence of the bovine bacillus in human tuberculosis at Algiers in 1969 Archives. Institut Pasteur D"Algerie. 48: 93-101. PMID 5005852 |
0.308 |
|
| 1968 |
Chaulet P, Boulahbal M, Grosset J. Acquired resistance to antibiotics of the tuberculosis bacillus in the Algiers area from 1963 to 1967. Importance and epidemiologic significance Revue De Tuberculose Et De Pneumologie. 32: 542-551. PMID 4992209 |
0.332 |
|
| 1968 |
Chaulet P, Abderrahim K, Grosset J, Larbaout D. Clinical experience in Algeria of intermittent treatment of pulmonary tuberculosis with isoniazid and streptomycin twice-weekly Tubercle. 49: 81-82. PMID 4872961 |
0.337 |
|
| 1967 |
Chaulet P, Larbaoui D, Grosset J, Abdfrrahim K. Intermittent chemotherapy with isoniazid and streptomycin in Algiers Tubercle. 48: 128-136. PMID 6058030 |
0.313 |
|
| 1967 |
Grumbach F, Canetti G, Grosset J, Le Lirzin M. Late results of long-term, intermittent chemotherapy of advanced, murine tuberculosis: Limits of the murine model Tubercle. 48: 11-26. PMID 6034625 |
0.445 |
|
| 1964 |
CANETTI G, RIST N, GROSSET J. PRIMARY DRUG RESISTANCE IN TUBERCULOSIS The American Review of Respiratory Disease. 90: 792-799. PMID 14211467 |
0.338 |
|
| 1964 |
Grumbach F, Canetti G, Grosset J. Further experiments on long-term chemotherapy of advanced murine tuberculosis, with emphasis on intermittent regimes Tubercle. 45: 125-135. PMID 14161911 |
0.342 |
|
| 1963 |
THIBIER R, LEPEUPLE A, VIVIEN JN, GROSSET J. RESULTS OF CHEMOTHERAPY AMONG 221 PATIENTS WITH PULMONARY TUBERCULOSIS DUE TO BACILLI INITIALLY SENSITIVE TO PRINCIPAL ANTIBIOTICS (FOLLOW UP OF 2 TO 5 YEARS) Revue De Tuberculose Et De Pneumologie. 27: 541-550. PMID 14073265 |
0.337 |
|
| 1960 |
CANETTI G, GRUMBACH F, GROSSET J. Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid The American Review of Respiratory Disease. 82: 295-313. PMID 13807426 |
0.347 |
|
| 1956 |
CANETTI G, GROSSET J. Late positivization of cultures of tuberculosis bacilli; its relation to isoniazid resistance Revue De La Tuberculose. 20: 1053-1061. PMID 13421327 |
0.31 |
|
| Show low-probability matches. |